Pharmaceutical - GlaxoSmithKline, Germany

Filter

Current filters:

GlaxoSmithKlineGermany

Popular Filters

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

Back to top